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Abstract
Background: Diabetes is a hormonal disorder that affects an estimated three hundred million people worldwide.
In this review (meta-analysis) of the literature, we carefully analyzed the limits and methods of the management of
diabetes in adolescents and adults.
Objective: The study focused on the identification of technologies and therapeutic procedures currently used and
tried to identify possible factors for future improvement.
Methods: The literature review was carried out on search engines like: PubMed, ADA, Google Scholar and
Google Patents. According to our search criteria, the selected articles were analyzed regarding evidence and critical
issues reported by patients and clinicians. The results were then compared with the recalls of the U.S. Food and
Drug Administration (FDA).
Results: The currently in use drugs and the insulin infusion systems vary a lot and simultaneous develop of new
technology adds to existing chaos. This study revealed possible areas for improvements both from a technological
and a medical point of view. For instance: the multiple causes related to the different timing of insulin absorption
according to the insertion site, the design of new algorithms focused on simplification of practical activities, and the
identification of new methods for training patients and families on the different device’s functions. Moreover, some
critical points were emerged related to the current limitations and lack of interchangeability between sensors for
monitoring vital parameters. This condition restricts the correct sensor selection according to the patient’s personal
preference, age and needs. However, the lack of interchangeability between different devices limits the choice of the
most appropriate monitoring software and data storage.
Conclusions: The collaboration between medical doctors and biomedical engineers is of great importance when
analyzing available medical devices for the purpose, identifies possible weaknesses, technical problems, and areas
for improvements. Moreover, multi-specialist collaboration is important to conceive new methods of training for
patients and families.
Keywords: Diabetes type 1; Infusion pump; Technical problems;
European norms; Medical devices; Self-management; CGM; Stylus
injectors; Glucometers; Software management
Abbreviations
CGM: Glucose Monitoring In Continuous; CG-EGA: Continuous
Glucose-Error Grid Analysis; CSII: Continuous Subcutaneous Insulin
Infusion; DM1: Diabetes type 1; DM2: Diabetes type 2; EGA: Error
Grid Analysis; IFCC: International Federation of Clinical Chemistry
and Laboratory Medicine; MARD: Median Absolute Relative
Difference; NIST: National Institute of Standards and Technology
Introduction
Diabetes is a hormonal disorder that affects around three hundred
million people worldwide [1]. Several therapies have been proposed
and a good compliance to treatment offers patients a good quality of
life. Diabetes is a disease characterized by a group of metabolic
disorders caused by defects of insulin’s secretion and / or activity. The
first condition is represented by a pancreas inability to produce insulin
and the latter is characterized by incorrect use of normal secreted
insulin (insulin resistance). Produced in the beta cells from the
Langerhans islets, insulin has a dual function: to transport glucose
from the bloodstream to the body's cells, where it is converted into
energy and it is involved in the anabolic metabolism of glycogen.
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Glucose, produced by the digestion of food, is transported by the blood
to all body cells. The rate of glucose in the blood is called glycemia.
Insulin is essential to allow the cells to use glucose as an energy source.
Diabetes is divided into mellitus TYPE1 and TYPE2:
Diabetes type 1 (DM1) is characterized by immune-mediated
destruction of pancreatic beta cells with absolute insulin deficiency.
This condition needs to be treated with insulin injections or
administered through a pump. DM1 appears more frequently in
children and adolescents and accounts for about 5% -10% of all cases
of diabetes in the world.
Diabetes type 2 (DM2) can be characterized by two conditions:
inadequate insulin’s secretions or peripheral insulin resistance. This is
by far the most common form of this disease, with 90% - 95% of cases.
DM2 usually can be controlled with diet, physical activity and oral
drugs but, in a high percentage of patients, insulin administration via
syringes or infusion pumps are needed. Several clinical trials show that
obesity and being overweight can cause the onset of type 2 diabetes.
In this paper, we present a review of the literature about the limits
and methods of management of diabetes in adolescents and adults. The
goal of the study was identify technologies and therapeutic procedures
currently used for diabetes’ treatment and monitoring and
subsequently, highlighting possible areas for improvement. The aim
was analyzing challenges and limits of currently available medical
devices for the management of diabetes. The focus has been extended
to stylus injectors, insulin pumps, sensors for Glucose Monitoring in
Continuous (CGM), glucometers and finally the artificial pancreas.
Therefore, in this paper we collected the European regulations for
manufactures. The study highlighted shows possible ideas for both
technological and scientific improvement.
Methods
Research setting
The study was conducted at Bambino Gesu’ Children’s Hospital,
Rome Italy. The Hospital encourages healthcare providers to establish
an open and friendly communication relationship with patients and
families. Moreover, healthcare providers are recommended to provide
accurate information about medical conditions and treatments, that
can help patients and families deal with the illness in a more informed
manner.
Research method
The literature review was carried out via the major search engines
(PubMed, ADA, Google Scholar, Google Patents, CDA) considering
the following keywords: diabetes, insulin pump, glucometer, biosensor,
pen injector, oral hypoglycemic agents, insulin therapy, pancreas
artificial, closed-loop, CGM, continuous Subcutaneous Insulin
Infusion (CSII). From the first analysis (n ° 2000 Articles) were selected
abstracts and relevant full text of interest. The research led to the
selection of the 15 items listed in the references. From the articles
selected were analyzed evidence and critical issues reported by patients
and clinicians, exposing the current technological advances aimed at
overcoming those limits (bio-artificial pancreas, nano-biosensors,
closed loop system). The selection of publications was performed
according to: number of citations, year of publication (2004-2013), IF
of the journal, significance of the results and published data the
authority of the authors (we chose to consider only items written by
diabetologists who strongly contributed to the scientific community
taking part of National or International commission and or authors of
guideline or medical books) and, finally, the importance of the
conference if the article was presented. Finally, we defined the role that
biomedical engineer must have to introduce these improvements in
therapy for the treatment of diabetes.
Emergence was compared with the recall of the U.S. Food and Drug
Administration (FDA) to the manufacturers of medical devices as
glucometer or insulin pumps and deepened through the information
made available by manufacturers.
Therefore in this paper we collected the European regulations for
manufactures.
Data Analysis
Stylus injectors
The pen, or pen needle, is very practical and convenient for easy to
control diabetes. They can be recharged or disposable and are visually
similar to a pen. In the case of rechargeable Stylus injectors, a reservoir
containing a vial of insulin (vial format pencil), whose apex is present
with a wheel which can be set and modified from time to time,
representing the doses needed for the patient. On one end there is a
button to release insulin while at the opposite side (tip) there is the
needle.
The advantages found by clinicians and users are: the ability to set
the amount of insulin with extreme simplicity (it is set to a numeric
selector), the needle is disposable and the dimensions of the stylus
injectors are reduced in order to make discreet its use. The main
disadvantage is that the units are not divisible, therefore it’s not
possible to use fractional units and this seriously limits treatment’s
adaptation for patients. In addition, when different types of insulin are
needed, more stylus injectors would be also needed [2-5].
Insulin pumps
The insulin pump is a small precision electro-mechanical device
that releases insulin into the body via a thin plastic tube (or infusion
set).
The infuser is a long thin plastic tube (thin plastic tubing), which
connects the pump to a small needle or flexible cannula, inserted
through the skin at the point of infusion (infusion site), usually in the
abdominal area in contact with the interstitial fluid. The infuser can be
held under the skin for about three days, after which it must be
replaced to avoid problems of infection. Unfortunately, the pump is not
able to self-define the correct insulin dosage based on the blood
glucose measurements. The pump is a precise instrument controlled by
a small programmable computer, which releases insulin in previously
set dosage (CSII) according to diabetologist prescription [6]. The pump
can be programmed to release the drug at any time. However, the
patient must check the blood glucose levels several times a day, a factor
that, in parallel, requires much more attention by the patient compared
to traditional systems of injection [6]. Some Insulin pumps are self-
lock in case of hypoglycemia thanks to special sensors [7].
Sensors for glucose monitoring in continuous (CGM)
A system for continuous measurement of blood glucose consists of a
subcutaneous sensor which detects the concentration of glucose in the
interstitial fluid. This system is connected to a transmitter that sends
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data to a receiver handheld which processes all information in order to
adjust the insulin infusion (by the patient). Technological advances
have increased precision and accuracy of analytical biosensors. The
sensors currently available can reach a maximum MARD (Median
Absolute Relative Difference), including measurement of blood glucose
and blood glucose sensor of reference, between 11% to 14% [7].
Crucial indicator for the prescription of an effective therapy, but
nevertheless it cannot be considered as an absolute indicator [8]. The
MARD, as the Continuous Glucose-Error Grid Analysis (CG-EGA), is
a Windows-based, statistical program designed to be used by the
diabetes technology industry for the evaluation of continuous glucose
monitoring devices. It is a logical extension of the original error grid
analysis (EGA), which was developed to assess the clinical accuracy of
patient-determined blood glucose values using either estimation or
self-monitoring blood glucose systems. CG-EGA is based on the idea
that information, generated by a monitoring system, should be reliable
enough to result in clinically accurate decision. The CG-EGA
technology was originally developed by Drs. William Clarke and Boris
Kovatchev at the University of Virginia in Charlottesville, VA, USA.
Glucometers: A portable medical device is able to estimate with
good approximation the glucose concentration in the blood. To
estimate the blood glucose, the glucometer analyzes a small drop (1μL)
of blood - usually taken from fingertip - on a special test strip. In most
of the models, the glucose content in the blood sample activates an
enzymatic reaction oxidizes by the presence of the enzyme glucose
oxidase in the test strip; this oxidation produces a color change or an
electrical current (depending on the model) convertible to glucose
value [8].
Software Management
The main goal is to facilitate the control of the variance as a function
of glycemic carbohydrate ingested and insulin units needed. The
currently available devices, interfaced with PC, have their software for
the storage and consultation of recorded data, allowing the
visualization of the parameters recorded for more than 24 hours [9].
European Norms
The European regulations that manufacturers must follow are (from
the most recent to the most dated):
UNI EN ISO 15197:2013: Systems of in vitro diagnostic assay -
Requirements for systems for self-testing of blood glucose monitoring
in the treatment of diabetes mellitus.
Directive EN 61326-1:2006: Electrical equipment for measurement,
control and laboratory use - EMC requirements - Part 1: General
requirements.
Directive EEC / EAEC / EC n ° 79 of 27/10/1998: 98/79/EC:
Directive of the European Parliament and of the Council of 27 October
1998 on in vitro diagnostic medical devices.
Directive 1999/5/EC of the European Parliament and of the Council
of 9 March 1999 on radio equipment and telecommunications terminal
equipment and the mutual recognition of their conformity.
Directive 93/42 EEC for Medical Devices (abbreviated as DDM
93/42).
Reference Methods for the execution of medical devices validation
tests:
Standard of the National Institute of Standards and Technology
(NIST).
Standards and Recommendations of the ‘International Federation of
Clinical Chemistry and Laboratory Medicine (IFCC)’.
Recall
After this first phase we checked the major recall of FDA to the
manufacturer of devices (Figure 1), numbers of recalled (Figure 2).
Therefore, we analyzed the why of the recalled to understand if
there were some common factors to be studied, to perform the
management of diabetes with devices (Figure 3).
The analysis was principally focused on glucometer and insulin
pump. We studied the way of recalls, the motivation (e.g., was analyzed
also the hardware that caused the error) and the risk for the patients as
showed by diagrams on (Figure 4).
Figure 1: Number of recall for each manufacturer.
Figure 2: Way of recalls by FDA.
Figure 3: Kind of hardware involved 3a) for Glucometer 3b) for
Insulin Pump.
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Figure 4: Alert percentage divided by type of device’s defects or
user’s error.
Results
The intent of this study was to identify the state of art of the limits
and methods of management of diabetes type 1 and 2 through the
literature analysis.
Various are the drugs and the insulin infusion systems currently in
use and under development [10].
Great is the industry attention to miniaturize all devices, with the
use of nanotechnology, as well as to study biomaterials that are more
suitable for insulin infusion.
Among many topics covered in the literature (Table 1), there are
three issues considered of greater impact in the short-medium term.
Factors Desired improvements
Insulin administration Identification of new techniques to
increase the rate of absorption of
insulin (ultra rapid wording, dosing in
other compartment, warmth the
infusion site)
Training Identify new methods and training for
patients and their families to facilitate
the use of all the functions of the
various devices that can be used for
the monitoring and treatment of
diabetes type I and II
Management software and
communication protocols
Example: 1) Communication between
glucose sensor and insulin pump:
make the connections more reliable; 2)
Interoperability of devices and
interfacing software: standardization of
the communication protocol
Improving the performance of the
algorithms
Example: 1) Recognition of glucose:
Reduce the false positive alarms of
hypoglycemia 2) Identify new
algorithms for insulin dose in closed
loop configuration
Table 1: Objectives to be achieved to improve performance.
Lack of know how about the time of absorption of insulin, that is
currently not less than 15 min [11,12]. Currently there are no studies
that define the optimal measurement site, but it is known that there are
different concentration of glucose in the blood compare to the
interstitial fluid [13]. It is well shown the 'importance of a constant
glucose concentration in the blood and prevention of hypoglycemia or
hyperglycemia, a result of improper use of insulin pump (CSII). In
addition, the insertion of interstitial or intra-cutaneous sensors [14] is
often problematic due to poor training, as well as to the currently
available intrinsic technological limits of (materials, biological
component and hardware) [15-17].
As there is no standardized protocol for communication between
devices, each manufacturer adopts its own software, confusing in the
user, and limiting the use and interpretation of the data (useful
purpose in a proper and continuous monitoring of clinical parameters
of diabetic subjects).
The frenetic introduction into the market of new devices by the
manufacturers does not allow the development of algorithms able to
minimize detection errors of the data [18,19].
The major leaders in the field of biomedical instrumentation for
diabetics have proven to be: Abbot, AgaMatrix, Animas, Arkay, Bayer,
Bayer, BIONIME, Diabestic Supply of Suncoast, Diagnostic Devices,
Dexcom, Lifiscan, Medtronic, Menarini, Nova Biomedical, Roche,
Sanofi Aventis. Topic of scientific discussion now turns out to be the
finalization of various systems "closed-loop" pointing to the best
technological solution that takes into account all the variables that
describe the biological system. The main difficulties in the
development are related to the difficulties in reproduction of the
physiology of insulin and glucose in the data due to the complexity of
the human body.
The analyses of recalls showed:
For glucose meters, 59% of the problems of the devices are data
from 'hardware rather than the software (41%).
77% of the insulin pumps considered encountered problems of
hardware rather than software (23%) and this is a critical issue that
could lead to a bad dose of insulin in patients with consequent effects
on health.
In 22% of cases, the user induces problems in the management of
the device, because of bad training by the staff, or inadequate interface
to the user type.
In addition, the subjectivity of the disease, which is not a negligible
element since each patient typically receives a different treatment,
affects the therapy by artificial pancreas that cannot be standardized
[20-23].
Discussions
The hospital and industrial research centers should endeavour to
improve existing technologies in line with the daily needs of patients.
Moreover, it would be important to identify new:
Hardware, customized on the patients target;
Systems that can reduce the problems of interoperability between
devices;
Semi-automatic calibrations to reduce possible operating errors
[24].
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Bambino Gesu' Children's Hospital, by the way of great result on a
telemedicine case study [25,26], is developing a new Network to help
the adolescent patients and their family. By a new App for Android
Tablet a Team of Engineers and Doctors are looking to have a standard
interface to analyze the diabetic patient data on Telemedicine follow
up.
Evaluating the processes of absorption of insulin would facilitate the
identification of the more appropriate dosage and reduce the
absorption (with inevitable positive impact on the levels of
glycosylated hemoglobin), a more appropriate treatment that also
means a higher quality of life and reduced direct (health and non-
health) and indirect costs. The synergy between Clinical, Biomedical
Engineers and Computer Services is of great importance to problems
resolution and to identify new methods for training for patients and
their families [26,27]. The regulations currently in force have not been
updated the last five years despite the strong development and
innovative technologies.
Conclusion and Future Work
The study highlighted possible ideas for both technological and
scientific improvement, presenting possible new studies to be
undertaken, for example about: evaluation of different times
depending on the absorption of insertion sites, development for
algorithms focus on simplification of business routine and
identification for new training techniques for patients and their
families on the use of all functions that can be set on different devices.
Moreover, critical issues related to the current limits for
interoperability between sensors emerged. Insulin pumps and blood
glucose meters, should be chosen according to patient’s needs, age and
personal perceived convenience of use. In addition, the lack of
interoperability between devices connected to computers, causes
limitations in the choice of software, monitoring and archiving
parameters, more 'suitable and intuitive by different users.
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